Tuberculosis remains a persistent global health challenge, infecting millions annually and causing significant morbidity and mortality. Despite considerable advances in treatment, early and reliable diagnosis remains a stumbling block, especially in low-income regions. Traditional methods, including sputum microscopy and culture, suffer from limitations such as lengthy processing times and difficulties in obtaining sputum samples from certain patient populations, including children and HIV co-infected individuals. It is within this clinical landscape that urinary biomarkers, such as lipoarabinomannan—a glycolipid component of the mycobacterial cell envelope—have garnered attention as promising targets for noninvasive TB diagnostics.

The newly developed lab-in-a-cartridge integrates a microfluidic chip embedded with biosensors capable of detecting minute concentrations of urinary LAM with remarkable specificity and sensitivity. This critical innovation addresses the need for point-of-care solutions that eliminate the dependency on centralized laboratories and highly trained personnel. The device’s architecture centers on a compact cartridge where urine samples flow through microchannels coated with high-affinity capture antibodies, facilitating the selective binding of LAM molecules. Subsequent transduction events translate these molecular interactions into electrical signals, enabling quantitative analysis with rapid turnaround.

What sets this platform apart is not only its analytical precision but also its portability and ease of use. The entire assay is automated within the sealed cartridge, obviating the risk of contamination and human error. Once a patient’s urine sample is introduced, the cartridge interfaces with a handheld reader that executes the measurement, processes data, and displays the results within minutes. This seamless workflow contrasts starkly with conventional testing paradigms that can take days or even weeks, underscoring the system’s potential to expedite clinical decision-making and treatment initiation.

The researchers’ rigorous validation of this technology involved extensive clinical trials encompassing diverse patient cohorts, including those co-infected with HIV—a group notoriously challenging to diagnose due to atypical disease presentation. Data demonstrated that the lab-in-a-cartridge system exhibited superior diagnostic accuracy relative to existing urinary LAM assays and sputum-based techniques, with enhanced ability to detect early-stage and extrapulmonary TB. Moreover, the assay’s quantitative output provides nuanced insights into disease burden, paving the way for its use in monitoring treatment efficacy and progression.

Beyond laboratory performance, the design team emphasized sustainability and cost-effectiveness. The cartridges are fabricated using low-cost polymers suitable for mass production, and the handheld reader is intended to be durable and battery-operated for field use in remote or underserved regions. This alignment with real-world operational constraints reflects a deep understanding of the socio-economic barriers that have historically impeded TB control efforts.

The implications of this technological breakthrough extend well beyond tuberculosis. The modular nature of the lab-in-a-cartridge allows for customizable biosensor arrays, potentially enabling multiplexed detection of other infectious diseases, biomarkers, or environmental toxins. Such adaptability could transform point-of-care diagnostics and surveillance, fostering responsive healthcare ecosystems capable of addressing diverse public health threats rapidly and efficiently.

Additionally, the integration of precise urinary LAM measurement into this device taps into growing recognition of urine as an underutilized biological fluid for noninvasive diagnostics. Unlike sputum or blood collection, urine sampling is painless, straightforward, and generally more acceptable to patients, offering practical advantages for widespread screening programs and repeated testing scenarios.

The research team’s multidisciplinary approach, combining expertise in bioengineering, microbiology, and clinical medicine, was pivotal in translating this conceptual framework into a tangible product. They meticulously optimized the antibody-antigen interactions, fluid dynamics within the microchannels, and signal transduction mechanisms to achieve reproducible, high-fidelity detection that could withstand the variabilities inherent in biological samples and field environments.

Furthermore, the system’s data handling capabilities incorporate digital storage and connectivity features, unlocking opportunities for integration with electronic health records and epidemiological databases. Such connectivity is vital for real-time surveillance of tuberculosis outbreaks and for tailoring public health interventions with granular, localized insights.

While the technology is poised for transformative impact, further work remains to expand its accessibility and scalability. Regulatory approvals, manufacturing scale-up, distribution logistics, and user training are critical next steps to ensure this innovation moves seamlessly from the lab to the frontlines of TB control worldwide.

In conclusion, this lab-in-a-cartridge system exemplifies the confluence of miniaturization, biomolecular science, and engineering to deliver a diagnostic tool that is as practical as it is powerful. Its ability to provide rapid, accurate, and noninvasive tuberculosis detection directly in resource-limited settings heralds a new era in infectious disease management—one where lifesaving diagnoses are no longer bottlenecked by geography or infrastructure, but rather enabled by smart, accessible technology.

Subject of Research: Real-time tuberculosis detection via urinary lipoarabinomannan measurement using a lab-in-a-cartridge platform.

Article Title: Lab-in-a-cartridge for real-time detection of tuberculosis via precise measurement of urinary lipoarabinomannan.

Article References:
Heo, W., Wang, Q., Choi, S. et al. Lab-in-a-cartridge for real-time detection of tuberculosis via precise measurement of urinary lipoarabinomannan. Nat Commun 16, 10299 (2025). https://doi.org/10.1038/s41467-025-65217-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65217-w

Tuberculosis remains a significant global health challenge. In 2023 alone, TB accounted for 1.25 million deaths worldwide, with a concerning 13% of those fatalities occurring among individuals living with HIV. The traditional diagnostic approach hinges fundamentally on the collection and analysis of sputum samples, which involve a physically demanding process of deep coughing to expectorate lung secretions. This method has been the cornerstone of TB diagnosis as recommended by international health organizations like the World Health Organization (WHO). However, as the research highlights, such techniques are fraught with limitations, especially for individuals battling advanced stages of HIV.

One of the central tenets of the study emphasizes that many individuals living with HIV often face difficulties in producing adequate sputum samples. It has been observed that over half of patients with advanced AIDS are unable to provide these crucial samples. Moreover, even when sputum samples are obtained, the concentration of Mycobacterium tuberculosis can be prohibitively low, rendering standard diagnostic tests ineffective. In light of these challenges, researchers sought an alternative that could offer a reliable diagnostic avenue for this vulnerable demographic.

The Stool4TB project, supported by the European and Developing Countries Clinical Trials Partnership (EDCTP), aimed to explore the feasibility of employing the Xpert MTB/RIF Ultra test on stool samples. This molecular diagnostic tool, currently in use for respiratory samples, has already been notably beneficial for pediatric patients who also struggle with sputum production. The backdrop for this research involved extensive fieldwork, with trials taking place across three African nations – Eswatini, Mozambique, and Uganda – between December 2021 and August 2024. A substantial cohort of 677 patients aged 15 and older was enlisted, all living with HIV and suspected of having TB, allowing researchers to gather a diverse array of biological samples, including sputum, urine, stool, and blood.

Amidst the clinical landscape, the challenges associated with diagnosing TB in patients with HIV infections are particularly pronounced. As George William Kasule, a promising doctoral candidate at ISGlobal, points out, individuals living with HIV exhibit a heightened susceptibility to pulmonary tuberculosis, yet conventional diagnostic tests often fall short in sensitivity. This discrepancy underlines the necessity for alternative testing methods that can capture a broader spectrum of potential TB cases. The research team utilized a microbiological reference standard based on three WHO-recommended tests to establish a comparison with the results from the Stool Ultra test.

The findings from this comprehensive study reveal critical insights. The sensitivity of the stool-based Xpert Ultra test was observed to be 23.7%, with an impressive specificity rate of 94%. However, what is particularly striking is how sensitivity escalated to 45.5% among patients with CD4 counts falling below 200 cells/μl. This marker is indicative of advanced HIV disease, and it is within this population where the risk of contracting opportunistic infections such as tuberculosis intensifies. The results prompt a broad re-evaluation of existing diagnostic practices, advocating for the integration of stool testing as an adjunctive tool for TB diagnosis.

Dr. Alberto L. García-Basteiro, a leading researcher at ISGlobal and the head of the Vaccine and Immune Response to Infections Unit at Hospital Clínic de Barcelona, emphasizes the transformative nature of these findings. The Stool Ultra test can not only identify additional TB cases that standard tests like TB-LAM, sputum Ultra, or culture may overlook, but it also offers a level of efficacy that is comparable to conventional sputum tests for patients in advanced AIDS stages. This insight brings to light a crucial benefit of utilizing stool samples – the ability to affirm a diagnosis even in scenarios where respiratory specimen collection is not feasible or fails to provide conclusive results.

As such, the potential of utilizing stool samples for TB detection, particularly in populations with HIV, is underscored by the pressing need for improved diagnostic strategies. The study demonstrates that such non-invasive methods can play a pivotal role in enhancing TB diagnosis in adults facing significant health challenges. This paradigm shift could usher in a new era of TB diagnostics, underscoring a glaring need for accessible and reliable testing methods that cater to the unique needs of populations traditionally marginalized in clinical diagnostics.

In summary, the findings from the Stool4TB project illuminate the viability of stool samples as an essential component in the diagnostic toolkit for tuberculosis, especially for individuals living with HIV. With substantial data backing this approach, healthcare providers and policymakers are urged to reconsider existing diagnostic frameworks that primarily rely on sputum samples. The emerging evidence from this research supports the notion that by embracing innovative testing methods, significant strides can be made toward combating the global TB epidemic—ultimately reducing morbidity and mortality in one of the most vulnerable populations today.

The significance of these findings cannot be overstated. As researchers continue to refine and expand upon the application of the Xpert MTB/Ultra test for stool samples, the overarching goal remains clear: to enhance accuracy in TB diagnosis, particularly for those who face barriers to traditional testing methods. The landscape of TB diagnostics is poised for a substantial evolution, and the implications of this research hold the promise of saving lives and improving health outcomes for countless individuals worldwide.

Subject of Research: People Living with HIV and Tuberculosis
Article Title: Stool Tests Could Revolutionize Tuberculosis Diagnosis in HIV-Positive Adults
News Publication Date: October 2023
Web References: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00013-8/fulltext
References: Kasule, G., Hermans, S., Acacio, S., et al, Performance of stool Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis among adult people living with HIV: a prospective multicentre diagnostic study. Lancet Microbe (2025).
Image Credits: Not Available

Keywords: Tuberculosis, HIV, Diagnostic Testing, Public Health, Molecular Diagnostics, Stool Sample Analysis, CD4 Count, Xpert MTB/RIF Ultra.